Accession Number:

ADA415519

Title:

In Situ Gene Therapy for Prostate Cancer: Development of Systemic Anti-Tumor Immunity

Descriptive Note:

Annual rept. 31 Dec 2001-30 Dec 2002

Corporate Author:

BAYLOR COLL OF MEDICINE HOUSTON TX

Personal Author(s):

Report Date:

2003-01-01

Pagination or Media Count:

16.0

Abstract:

Although to our knowledge there are no dearly defined tumor antigens for prostate cancer, based on our preliminary data we of the opinion that specific gene-modified cell-based immunotherapy protocols could result in the generation of a systemic anti-metastatic immune response. We have shown that IL-12B7 transduced antigen-presenting cells APC can effectively induce an anti-tumor immunity that IL-12B7 modified prostate cancer cell vaccine strategies can generate a systemic anti-tumor immune response and, that IL-12B7 gene delivery has specific therapeutic effects against bone metastases. We proposed to test the efficacy of specific therapeutic approaches incorporating novel biological concepts of IL-12 gene modified cell-based therapy using preclinical models of metastatic prostate cancer.

Subject Categories:

  • Biochemistry
  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE